Qelbree Capsule, Extended Release
Product Images NDC 17772-132

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Qelbree (NDC 17772-132). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Supernus Pharmaceuticals, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Qelbree 01)

Chemical structure of viloxazine hydrochloride shown as a 2D molecular diagram with aromatic and heterocyclic rings, including oxygen and nitrogen atoms.*

FDA Label Image

Figure 1 (Qelbree 02)

A forest plot showing fold change and 90% confidence intervals for Cmax and AUC pharmacokinetic parameters of QELBREE (viloxazine hydrochloride) in special populations with varying degrees of hepatic and renal impairment. The x-axis represents change relative to reference on a logarithmic scale from 0.5 to 4. Fold changes for mild, moderate, and severe impairment groups are plotted with confidence intervals, illustrating variability in drug exposure.*

FDA Label Image

Figure 2 (Qelbree 03)

A forest plot depicting pharmacokinetic changes in Cmax and AUC with associated 90% confidence intervals for methylphenidate, lisdexamfetamine dimesylate, and paroxetine relative to a reference. The x-axis measures fold change relative to reference from 0.8 to 1.5, showing variability in drug exposure parameters.*

FDA Label Image

Figure 3 (Qelbree 04)

A figure showing fold change and 90% confidence intervals for pharmacokinetic parameters (Cmax and AUC) of several interacting drugs relative to a reference. The x-axis represents change relative to reference on a logarithmic scale from 0.5 to 16. Interacting drugs include methylphenidate, lisdexamfetamine dimesylate, CYP3A4 substrate midazolam, CYP2D6 substrate dextromethorphan, and CYP1A2 substrate caffeine, with different fold changes depicted for each.*

FDA Label Image

Principal Display Panel (100 mg Capsule Bottle Label)

Qelbree 100 mg extended-release capsules label for oral use by Supernus Pharmaceuticals, Inc. The label indicates a 30-capsule count with directions for once daily dosing. It includes storage instructions, dosage recommendations pointing to prescribing information, and pharmacist dispensing guidance. The NDC code 17772-131-30 is visible along with a barcode.*

FDA Label Image

Principal Display Panel (150 mg Capsule Bottle Label)

Qelbree 150 mg extended-release capsules packaging label. The label shows the proprietary name Qelbree with viloxazine as the active ingredient, strength 150 mg per capsule. The carton contains 30 capsules for oral use with once-daily dosing. Manufactured by Supernus Pharmaceuticals, Inc. Additional storage and dispensing instructions are included along with the NDC 17772-132-30 and barcode.*

FDA Label Image

Principal Display Panel (200 mg Capsule Bottle Label)

Qelbree 200 mg extended-release capsules package label showing 30 capsules. Contains viloxazine hydrochloride with instructions for pharmacist to dispense accompanying medication guide. Manufactured by Supernus Pharmaceuticals, Inc. Label includes storage temperature and usage notes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.